Abstract | OBJECTIVES: METHODS: All patients who initiated interferon- ribavirin therapy at The Ottawa Hospital Viral Hepatitis Clinic (Ottawa, Ontario) between August 2003 and January 2007 were identified using a computerized clinical database. The baseline characteristics of OC recipients were compared with those of nonrecipients. The treatment-related side effect response to OC was assessed by c2 analysis. The key therapeutic outcomes related to weight, interferon dose reduction and treatment outcomes were assessed by Student's t test and c2 analysis. RESULTS: Twenty-five of 191 patients (13%) initiated OC use. Recipients had similar characteristics to nonrecipients, aside from prior marijuana smoking history (24% versus 10%, respectively; P=0.04). The median time to OC initiation was seven weeks. The most common indications for initiation of OC were anorexia (72%) and nausea (32%). Sixty-four per cent of all patients who received OC experienced subjective improvement in symptoms. The median weight loss before OC initiation was 4.5 kg. A trend toward greater median weight loss was noted at week 4 in patients eventually initiating OC use (-1.4 kg), compared with those who did not (-1.0 kg). Weight loss stabilized one month after OC initiation (median 0.5 kg additional loss). Interferon dose reductions were rare and did not differ by OC use (8% of OC recipients versus 5% of nonrecipients). The proportions of patients completing a full course of HCV therapy and achieving a sustained virological response were greater in OC recipients. CONCLUSIONS: The present retrospective cohort analysis found that OC use is often effective in managing HCV treatment-related symptoms that contribute to weight loss, and may stabilize weight decline once initiated.
|
Authors | Cecilia T Costiniuk, Edward Mills, Curtis L Cooper |
Journal | Canadian journal of gastroenterology = Journal canadien de gastroenterologie
(Can J Gastroenterol)
Vol. 22
Issue 4
Pg. 376-80
(Apr 2008)
ISSN: 0835-7900 [Print] Canada |
PMID | 18414712
(Publication Type: Comparative Study, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Antiviral Agents
- Cannabinoids
- Ribavirin
- Interferons
|
Topics |
- Adult
- Anorexia
(chemically induced, drug therapy)
- Antiviral Agents
(adverse effects)
- Cannabinoids
(pharmacology, therapeutic use)
- Dose-Response Relationship, Drug
- Female
- Hepatitis C, Chronic
(drug therapy)
- Humans
- Interferons
(adverse effects)
- Male
- Middle Aged
- Nausea
(chemically induced, drug therapy)
- Retrospective Studies
- Ribavirin
(adverse effects)
- Treatment Outcome
- Weight Loss
(drug effects)
|